Evidence map›Paper›PMID 35229496›Full record

ArticleACR open rheumatology2022

Presence and Implications of Anti-Angiotensin Converting Enzyme-2 Immunoglobulin M Antibodies in Anti-Melanoma-Differentiation-Associated 5 Dermatomyositis.

Christopher A Mecoli, Akira Yoshida, Julie J Paik, Cheng Ting Lin, Sonye Danoff, Hironari Hanaoka, Antony Rosen, Lisa Christopher-Stine, Masataka Kuwana, Livia Casciola-Rosen

Open access · goldAbstract read
In one paragraph

Article in ACR open rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Autoantibodies targeting angiotensin-converting enzyme 2 are prevalent and not induced by SARS-CoV-2 infection.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Christopher A MecoliJohns Hopkins University School of Medicine, Baltimore, Maryland.ORCID https://orcid.org/0000-0002-1429-8392
Akira YoshidaNippon Medical School Graduate School of Medicine, Tokyo, Japan.
Julie J PaikJohns Hopkins University School of Medicine, Baltimore, Maryland.ORCID https://orcid.org/0000-0001-8436-1601
Cheng Ting LinJohns Hopkins University School of Medicine, Baltimore, Maryland.
Sonye DanoffJohns Hopkins University School of Medicine, Baltimore, Maryland.
Hironari HanaokaKeio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5172-1102
Antony RosenJohns Hopkins University School of Medicine, Baltimore, Maryland.
Lisa Christopher-StineJohns Hopkins University School of Medicine, Baltimore, Maryland.ORCID https://orcid.org/0000-0002-7150-7306
Masataka KuwanaNippon Medical School Graduate School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8352-6136
Livia Casciola-RosenJohns Hopkins University School of Medicine, Baltimore, Maryland.ORCID https://orcid.org/0000-0002-4172-1539
Johns Hopkins University · USNippon Medical School · JPKeio University · JP

Funding

Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Antony Rosen · 2016 to 2026
$8.9M
Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to CancerR01AR073208 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI LIVIA A CASCIOLA-ROSEN, Ami Aalok Shah · 2018 to 2026
$5.2M
Optimizing the Approach to Identify Cancer-Associated MyositisK23AR075898 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI MECOLI, CHRISTOPHER · 2019 to 2023
$773k
Bill and Melinda Gates FoundationGates Philanthropy PartnersJapan Agency for Medical Research and Development 21ek0109531h0001NIAMS NIH HHS K23AR0739NIAMS NIH HHS K23 AR075898NIAMS NIH HHS K23AR075898NIAMS NIH HHS P30-AR070254NIAMS NIH HHS R01 AR-073208The Donald and Dorothy Stabler FoundationThe Huayi and Siuling Zhang Discovery FundThe Jerome L. Greene Foundation
6 · The paper itself

Abstract

objectivePatients with anti-melanoma-differentiation-associated 5 (anti-MDA5)-positive dermatomyositis (DM) share several striking similarities to patients with SARS-CoV-2. Our objective was to assess the prevalence of anti-angiotensin converting enzyme-2 (ACE2) immunoglobulin M (IgM) antibodies, found in patients with severe SARS-CoV-2, in two independent anti-MDA5-positive DM cohorts.

methodsAnti-ACE2 IgM antibodies were assayed by enzyme-linked immunosorbent assay (ELISA) in two anti-MDA5-positive DM cohorts: a predominantly outpatient North American cohort (n = 52) and a Japanese cohort enriched for new-onset disease (n = 32). Additionally, 118 patients with SARS-CoV-2 with a spectrum of clinical severity were tested for anti-MDA5 antibodies by ELISA.

resultsFive of fifty-two (9.6%) North American patients and five of thirty-two (15%) Japanese patients were positive for anti-ACE2 IgM. In the North American cohort, all five patients with anti-ACE2 IgM antibodies had proximal muscle weakness, had interstitial lung disease, were significantly more likely to receive pulse dose methylprednisolone (80% vs 30%, P = 0.043), and had worse forced vital capacity (median 59% predicted vs 78%, P = 0.056) compared with the anti-ACE2-IgM-negative group. In the Japanese cohort, all five anti-ACE2-IgM-positive patients also required pulse dose methylprednisolone, and three of five (60%) patients died. Japanese patients with anti-ACE2 IgM had significantly worse oxygenation, as defined by a lower partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio (233 vs 390, P = 0.021), and a higher alveolar-arterial oxygenation gradient (91 vs 23 mm Hg, P = 0.024) than the IgM-negative group.

conclusionWe describe anti-ACE2 IgM autoantibodies in two independent cohorts with anti-MDA5-positive DM. These autoantibodies may be biomarkers for severe disease and provide insight into disease pathogenesis.

Identifiers

PMID35229496
PMCPMC9096520
OpenAlexW4214511118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.